Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11319251 | 0.78 | FFAR1 (0.53) | SRCCYP2D6FFAR1 | |
| SCHEMBL3516304 | 0.77 | TAAR1 (0.52) | HTR2ATAAR1 | |
| SCHEMBL8712988 | 0.77 | LMNA (0.46) | TRPA1LMNAFFAR1HTR2ATAAR1 | |
| SCHEMBL9220590 | 0.77 | HTR2A (0.36) | SRCCYP2D6LMNAMAPK1TSHR | |
| SCHEMBL15259640 | 0.77 | TSHR (0.39) | SRCCYP2D6LMNAMAPK1TSHR | |
| SCHEMBL23199874 | 0.77 | TSHR (0.52) | TRPA1GSRSRCCYP2D6LMNA | |
| SCHEMBL143452 | 0.77 | LMNA (0.46) | TRPA1LMNAFFAR1HTR2ATAAR1 | |
| SCHEMBL6304003 | 0.77 | ESR1 (0.42) | TRPA1GSRSRCCYP2D6LMNA | |
| SCHEMBL1094363 | 0.77 | TSHR (0.52) | TRPA1GSRSRCCYP2D6LMNA | |
| SCHEMBL31261480 | 0.77 | TSHR (0.52) | TRPA1GSRSRCCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106397117-B | Reductive alcoholization and resolution method of cyclohexyl phenyl ketone | 六安佳诺生化科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-106397117-A | Reduction alcoholization and resolution method of cyclohexyl phenyl ketone | 安徽爱有澄生物科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-8551956-B2 | Compositions containing peptides with non-natural amino acids and methods of use | AVON PRODUCTS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | AVON PRODUCTS INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1998790-A2 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PRODUCTS, INC. (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007100874-A2 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PRODUCTS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-0820507-B8 | NDF PEPTIDES | AMGEN INC (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-0820507-B1 | NDF PEPTIDES | AMGEN INC (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1012186-B1 | USE OF A KGF PROTEIN PRODUCT(S) AND A GLP-2 PROTEIN PRODUCT(S) FOR THE PREPARATION OF A MEDICAMENT | AMGEN INC (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1012186-A2 | KERATINOCYTE GROWTH FACTORS AND USES THEREOF | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| US-5849705-A | Method for the treatment of Schwann cells in vivo | AMGEN INC. (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1998024813-A2 | KERATINOCYTE GROWTH FACTORS AND THEIR USE IN COMBINATION WITH GLUCAGON-LIKE PEPTIDE DERIVATIVES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0820507-A1 | NDF PEPTIDES | AMGEN INC. (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5686415-A | ADMINISTERING PEPTIDES DERIVED FROM CELL GROWTH FACTORS, PROMOTION OF GROWTH AND DIFFERENTIATION, TREATMENT OF COLITIS | AMGEN INC. (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1997035999-A2 | PRODUCTION OF VANILLIN | INSTITUTE OF FOOD RESEARCH (GB) | 1997-10-02 | — | — | WO | disclosed |
| US-5670342-A | NDF peptides | AMGEN INC. (US) | 1997-09-23 | — | — | US | disclosed |
| WO-1996031599-A1 | NDF PEPTIDES | AMGEN INC. (US) | 1996-10-10 | — | — | WO | disclosed |
| US-4785010-A | AGING RESISTANCE OF HUMANS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0124067-B1 | 2-(AMINOALKYL)-PYRROLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1986-12-17 | — | — | EP | disclosed |
| EP-0124067-A1 | 2-(Aminoalkyl)-pyrrole derivatives, process for their manufacture and their use | CASSELLA Aktiengesellschaft (DE) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | CUTA, NGLY1, LNPEP | TRPA1 2189/4885GSR 4506/4885SRC 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.